Vertex advances vx-548 in acute and neuropathic pain

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced that following the positive phase 2 results earlier this year and having reached agreement on the design of the pivotal development program with the u.s. food and drug administration (fda), vertex plans to advance the selective nav1.8 inhibitor vx-548 into phase 3 clinical trials in the fourth quarter of 2022. vertex also intends to initiate a phase 2 dose-ranging study of vx-548 in neuropathic pain by t
VRTX Ratings Summary
VRTX Quant Ranking